SNDX.US | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare

symbol		last	change	%chng	name	mcap	sector	wiki
SNDX	US				Syndax Pharmaceuticals Inc

Market global news for SNDX (US) Syndax Pharmaceuticals Inc

Global news - US chevrons indicate local prediction, arrows show global predictions

Today

	Syndax Pharmaceuticals (NASDAQ:SNDX) Receives "Buy" Rating from HC Wainwright dailypolitical - 4h ago - SNDX - link story
	Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright themarketsdaily - 12:45 Fri - SNDX - link story
	Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright theenterpriseleader - 12:45 Fri - SNDX - link story

previous days

	Syndax Pharmaceuticals (NASDAQ:SNDX) Receives "Buy" Rating from HC Wainwright dailypolitical - 4h ago - SNDX - link story
	Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright theenterpriseleader - 12:45 Fri 26 - SNDX - link story
	Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright themarketsdaily - 12:45 Fri 26 - SNDX - link story
	Peregrine Capital Management LLC Sells 23,941 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) themarketsdaily - 11:00 Fri 12 - SNDX - link story
	Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session marketscreener - 18:15 Tue 9 - SNDX - link story
	Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session eagletribune - 13:45 Mon 8 - SNDX - link story
	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) prnewswire - 21:15 Fri 5 - SNDX - link story
	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from Brokerages theenterpriseleader - 09:45 Thu 4 - SNDX - link story
	Dismantling Silos: Why Those Who Fight Cancer and Environmental Dangers Must Join Forces resilience org - 09:30 Thu 4 - SNDX - link story
	Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia ajmc - 00:00 Wed 3 - SNDX - link story
	Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright dailypolitical - 06:30 Sat 30 - SNDX - link story
	Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia eagletribune - 13:30 Thu 28 - SNDX - link story
	Syndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute Leukemia finanzen at - 05:30 Wed 27 - SNDX - link story
	FDA Grants Priority Review to Revumenib for R/R KMT2A+ AML/ALL onclive - 01:30 Wed 27 - SNDX - link story
	Syndax Says Revumenib NDA Granted FDA Priority Review marketscreener - 21:15 Tue 26 - SNDX - link story
	Syndax Pharmaceuticals (SNDX) Granted FDA Priority Review of NDA for Revumenib streetinsider - 20:30 Tue 26 - SNDX - link story
	Syndax Announces Appointment of Steven Closter as Chief Commercial Officer eagletribune - 13:00 Mon 18 - SNDX - link story